734 related articles for article (PubMed ID: 19246243)
1. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease.
Hanger DP; Anderton BH; Noble W
Trends Mol Med; 2009 Mar; 15(3):112-9. PubMed ID: 19246243
[TBL] [Abstract][Full Text] [Related]
2. Prospect of therapeutic approaches to tauopathies.
Roder HM
J Mol Neurosci; 2003 Apr; 20(2):195-202. PubMed ID: 12794313
[TBL] [Abstract][Full Text] [Related]
3. Further understanding of tau phosphorylation: implications for therapy.
Medina M; Avila J
Expert Rev Neurother; 2015 Jan; 15(1):115-22. PubMed ID: 25555397
[TBL] [Abstract][Full Text] [Related]
4. Tau phosphorylation and aggregation as a therapeutic target in tauopathies.
Badiola N; Suárez-Calvet M; Lleó A
CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):727-40. PubMed ID: 20942789
[TBL] [Abstract][Full Text] [Related]
5. Recent developments with tau-based drug discovery.
Iqbal K; Liu F; Gong CX
Expert Opin Drug Discov; 2018 May; 13(5):399-410. PubMed ID: 29493301
[TBL] [Abstract][Full Text] [Related]
6. Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders.
Kaur P; Khera A; Alajangi HK; Sharma A; Jaiswal PK; Singh G; Barnwal RP
Mol Neurobiol; 2023 Mar; 60(3):1690-1720. PubMed ID: 36562884
[TBL] [Abstract][Full Text] [Related]
7. A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies.
Giacomini C; Koo CY; Yankova N; Tavares IA; Wray S; Noble W; Hanger DP; Morris JDH
Acta Neuropathol Commun; 2018 May; 6(1):37. PubMed ID: 29730992
[TBL] [Abstract][Full Text] [Related]
8. RNA and protein-dependent mechanisms in tauopathies: consequences for therapeutic strategies.
Gallo JM; Noble W; Martin TR
Cell Mol Life Sci; 2007 Jul; 64(13):1701-14. PubMed ID: 17453144
[TBL] [Abstract][Full Text] [Related]
9. Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease.
Stancu IC; Ferraiolo M; Terwel D; Dewachter I
Adv Exp Med Biol; 2019; 1184():145-166. PubMed ID: 32096036
[TBL] [Abstract][Full Text] [Related]
10. Molecular Mechanisms in the Pathogenesis of Alzheimer's disease and Tauopathies-Prion-Like Seeded Aggregation and Phosphorylation.
Hasegawa M
Biomolecules; 2016 Apr; 6(2):. PubMed ID: 27136595
[TBL] [Abstract][Full Text] [Related]
11. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
12. Tau pathology in Alzheimer disease and other tauopathies.
Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
[TBL] [Abstract][Full Text] [Related]
13. O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer's disease and related tauopathies: analysis of the patent literature.
Bartolomé-Nebreda JM; Trabanco AA; Velter AI; Buijnsters P
Expert Opin Ther Pat; 2021 Dec; 31(12):1117-1154. PubMed ID: 34176417
[No Abstract] [Full Text] [Related]
14. Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology.
Leroy K; Ando K; Héraud C; Yilmaz Z; Authelet M; Boeynaems JM; Buée L; De Decker R; Brion JP
J Alzheimers Dis; 2010; 19(2):705-19. PubMed ID: 20110614
[TBL] [Abstract][Full Text] [Related]
15. Tau protein as a differential biomarker of tauopathies.
Sergeant N; Delacourte A; Buée L
Biochim Biophys Acta; 2005 Jan; 1739(2-3):179-97. PubMed ID: 15615637
[TBL] [Abstract][Full Text] [Related]
16. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance.
Jiang T; Yu JT; Zhu XC; Zhang QQ; Cao L; Wang HF; Tan MS; Gao Q; Qin H; Zhang YD; Tan L
Neuropharmacology; 2014 Oct; 85():121-30. PubMed ID: 24880087
[TBL] [Abstract][Full Text] [Related]
17. Intracellular and extracellular microtubule associated protein tau as a therapeutic target in Alzheimer disease and other tauopathies.
Avila J; Pallas N; Bolós M; Sayas CL; Hernandez F
Expert Opin Ther Targets; 2016 Jun; 20(6):653-61. PubMed ID: 26652296
[TBL] [Abstract][Full Text] [Related]
18. Posttranslational modifications of tau--role in human tauopathies and modeling in transgenic animals.
Chen F; David D; Ferrari A; Götz J
Curr Drug Targets; 2004 Aug; 5(6):503-15. PubMed ID: 15270197
[TBL] [Abstract][Full Text] [Related]
19. Regulation of neuronal microtubule dynamics by tau: Implications for tauopathies.
Venkatramani A; Panda D
Int J Biol Macromol; 2019 Jul; 133():473-483. PubMed ID: 31004638
[TBL] [Abstract][Full Text] [Related]
20. The role of tau phosphorylation and cleavage in neuronal cell death.
Chun W; Johnson GV
Front Biosci; 2007 Jan; 12():733-56. PubMed ID: 17127334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
